- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Omeros Corporation Reports Q4 and Full-Year 2025 Results
Biotech firm shares financial performance for past fiscal year
Mar. 31, 2026 at 9:48pm
Got story updates? Submit your updates here. ›
Omeros' financial report sheds light on the capital-intensive nature of the biotech industry and the company's ongoing efforts to advance its drug pipeline.Seattle TodayOmeros Corporation, a Seattle-based biopharmaceutical company, has reported its financial results for the fourth quarter and full-year 2025. The company highlighted key developments and milestones achieved during the past fiscal year.
Why it matters
As a publicly traded biotech firm, Omeros' financial performance and operational updates are closely watched by investors, industry analysts, and the broader healthcare community. The company's results provide insight into the state of its drug development pipeline and commercial operations.
The details
In its report, Omeros detailed revenue, expenses, and net income figures for Q4 2025 and the full 2025 fiscal year. The company also discussed progress on its lead drug candidates and provided guidance for the year ahead.
- Omeros reported its Q4 2025 and full-year 2025 financial results on March 31, 2026.
The players
Omeros Corporation
A Seattle-based biopharmaceutical company focused on developing and commercializing therapies to address immunologic and inflammatory disorders.
The takeaway
Omeros' latest financial report highlights the company's ongoing efforts to advance its drug development pipeline and maintain its commercial operations. As a key player in the biotech industry, Omeros' performance is closely watched by investors and industry observers.
